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The effect of chemical modification on the pseudocholinesterase and aryl acylamidase activities of purified 
human serum pseudocholinesterase was examined in the absence and presence of butyrylcholine iodide, the 
substrate of pseudocholinesterase. Modification by 2-hydroxy-5-nitrobenzyl bromide, N-bromosuccinimide, 
diethylpyrocarbonate and trinitrobenzenesulfonic acid caused a parallel inactivation of both pseudocholinesterase 
and aryl acylamidase activities that could be prevented by butyrylcholine iodide. With phenylglyoxal and 2,4- 
pentanedione as modifiers there was a selective activation of pseudocholinesterase alone with no effect on aryl 
acylamidase. This activation could be prevented by butyrylcholine iodide. N-Ethylmaleimide and p-hydroxy- 
mercuribenzoate when used for modification did not have any effect on the enzyme activities. The results suggested 
essential tryptophan, lysine and histidine residues at a common catalytic site for pseudocholinesterase and aryl 
acylamidase and an arginine residue (or residues) exclusively for pseudocholinesterase. 
The use of N-acetylimidazole, tetranitromethane and acetic anhydride as modifiers indicated a biphasic change 
in both pseudocholinesterase and aryl acylamidase activities. At low concentrations of the modifiers a stimulation 
in activities and at high concentrations an inactivation was observed. Butyrylcholine iodide or propionylcholine 
chloride selectively protected the inactivation phase without affecting the activation phase. Protection by the 
substrates at the inactivation phase resulted in not only a reversal of the enzyme inactivation but also an activation. 
Spectral studies and hydroxylamine treatment showed that tyrosine residues were modified during the activation 
phase. The results suggested that the modified tyrosine residues responsible for the activation were not involved 
in the active site of pseudocholinesterase or aryl acylamidase and that they were more amenable for modification 
in comparison to the residues responsible for inactivation. 
Two reversible inhibitors of pseudocholinesterase, namely ethopropazine and imipramine, were used as 
protectors during modification. Unlike the substrate butyrylcholine iodide, these inhibitors could not protect 
against the inactivation resulting from modification by 2-hydroxy-5-nitrobenzyl bromide, N-bromosuccinimide 
and trinitrobenzenesulfonic acid. But they could protect against the activation of pseudocholinesterase and aryl 
acylamidase by low concentrations of N-acetylimidazole and acetic anhydride thereby suggesting that the binding 
site of these inhibitors involves the non-active-site tyrosine residues. 
Although the physiological role of pseudocholinesterases 
(PsChE) has been obscure for many years, recent studies 
indicate that they may have some definite functions in the 
mammalian system. The possibility of PsChE acting as a 
post-translational precursor of acetylcholinesterase has been 
suggested by Koelle et al. [l]. Human serum PsChE has been 
demonstrated to act as a peptidase on substance P [2]. A 
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Trivial numes. Ethopropazine, 10-(2-diethylaminopropyl) pheno- 
thiazine; imipramine, N-(p-dimethylamiuopropyl) iminodibenzyl. 
Abbreviations. PsChE, pseudocholinesterase; AAA, aryl acyl- 
amidase; BCI, butyrylcholine iodide; HNBB, 2-hydroxy-5-nitro- 
benzyl bromide; (NOZ)3PhS03, 2,4,6-trinitrobenzenesulfonic acid; 
SDS, sodium dodecyl sulfate. 
Enzymes. Pseudocholinesterase or butyrylocholinesterase or 
cholinesterase or acylcholine acylhydrolase (EC 3.1 .I 23); aryl acyl- 
amidase or arylacylamide amidohydrolase (EC 3.5.1.13); acetyl- 
cholinesterase or acetylcholine acetylhydrolase or true cholinesterase 
(EC 3.1.1.7). 
soluble form of cholinesterase from bovine fetal serum has 
been shown to have peptidase activity on enkephalins and 
several other peptides [3]. Histocheinical studies on the visual 
pathway have suggested that PsChE or its endogenous sub- 
strate may be a neuroactive substance in the primate brain 
Human serum is a well known source of PsChE [S]. We 
[6], as well as others [7], have shown that an aryl acylamidase 
(AAA) activity is exhibited by human serum PsChE. Both the 
PsChE and AAA activities have been identified with the same 
protein on the basis of their identical behaviour on column 
chromatographic and affinity chromatographic procedures, 
gel filtration, gel electrophoresis, their coprecipitation by anti- 
PsChE antibody and identical response to potential 
cholinesterase inhibitors [6]. An interesting aspect of the AAA 
associated with human serum PsChE was its specific inhibi- 
tion by serotonin and activation by tyramine [6, 71. 
The bifunctional nature of PsChE exhibiting an AAA 
activity is reminiscent of the amidolytic and esterolytic 
activities exhibited by several purified proteases like chymo- 
trypsin, trypsin, carboxypeptidase A, elastase and thrombin. 
[41. 
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Table 1. Experimental c.onditions,for chemical rnodificztion q f  PsChE and A A A 
~~ 
Protein modifying reagent used Conditions of reaction for modification References 
HNBB and N-bromosuccinimide 
Diethylpyrocarbonate 
(NO&PhSO, and acetic 
anhydridc 
Phenylglyoxal and 
2.4-pentanedione 
N-Acetylimidazole and 
tetranitromethane 
N-Ethylmaleimide and 
p-h ydroxyniercuribenzoate 
thc reaction mixture in 20 niM sodium acetate buffer, pH 5.0 
containing the enzyme and 0.5- 10 mM HNBB was incubated 
at 0-4"C for 3 min; in the case of N-bromosuccinimide the reaction 
was carried out at 37 'C  for 15 rnin with 2.5-25 pM modifier 
diethylpyrocai-bonate, 0.5 - 10 mM in ethanol, was incubated with 
enzyme in 20 mM potassium phosphate buffer, pH 7.0 at  2 2 T  
for 15 min (ethanol in the reaction mixture was kept at 5% vjv 
which had no effect on enzymc activity) 
thc reaction mixture in 20 mM potassium phosphate buffer, pH 8.0, 
containing the enzyme and 1-20 mM (N02)3PhS03 was 
incubatcd at 37°C for 30 min; for acetic anhydride (1 -15 mM) thc 
pH of the reaction mixture was 7.0 in 100 mM phosphate buffer 
and the reaction was carried out at  37'C for 20 min 
the reaction mixture in 20 mM Hepes/NaOH, pH 7.5, containing 
the enzyme and 1-20 mM phenylglyoxal or 0.5- 10 mM 
2.4-pentanedione was incubated for 20 min at 37 "C 
the reaction mixture in 20 mM potassium phosphate buffcr, pH 7.0, 
containing the enzyme and 10- 300 mM N-acetylimidazole, was 
incubated at 37°C for 20 min; in the case of tetranitromethane the 
reaction was carried out in 20 mM Tris HCI buffer, pH 8.0, 
containing the enzymes and 0.021 -4.2 mM tetranitromethane in 
ethanol (5% vjv) at 37°C for 30 min 
the reaction mixture in 20 mM potassium phosphate buffer, pH 7.0. 
containing the enzyme and 0.1 -20 mM N-ethylmaleimide in 
ethanol (5% v/v) was incubated at 37°C for 30 min; for 
p-hydroxymercuribcnzoate, the reaction was in 20 mM Tris/HCl, 
pH 8.0, containing the enzyme and 0.2 - 2.0 mM 
p-hydroxymercuribenzoate at 37°C for 30 min 
[32, 331 
[15, 231 
[16, 3 i ]  
P51 
[16, 27-29] 
[301 
Some of these proteases have been shown to have non-identi- 
cal active centers for their esterolytic and amidolytic activities 
[S - 121. Moreover acetylcholinesterase from electric eel and 
basal ganglia has been suggested to have non-identical 
partially overlapping active centers for its esterase and acyl 
amidase activities [13]. In view of these findings and the re- 
ported protease activity attributed to serum PsChE [2], it was 
of interest to find out which amino acids are involved in the 
active centers of PsChE and AAA activities. In the present 
study we have used chemical modification of the purified 
human serum PsChE as a means to this end. Evidence for 
non-identical but overlapping active centers is presented. 
Moreover the stimulation of PsChE and AAA activities by 
modification of a class of tyrosine residues present at a site 
different from the active site has been demonstrated. 
MATERIALS AND METHODS 
Materiuls 
2-Hydroxy-5-nitrobenzyl bromide (HNBB), N-bromosuc- 
cinimide, diethylpyrocarbonate, 2,4,6-trinitrobenzenesulfonic 
acid [(N02)3PhS03], phenylglyoxal, 2,4-pentanedione, N- 
acetylimidazole, tetranitromethane, N-ethylmaleimide, p-  
hydroxymercuribenzoate, ethopropazine . HCl, imipramine 
. HC1 and choline derivatives were purchased from Sigma 
Chemical Co., USA. All other chemicals were either prepared 
or obtained as in [6]. 
Purificution qf human serum PsChE and enzyme assays 
PsChE from human serum was purified to homogeneity 
essentially as described earlier [6] with some modifications. 
The active fractions after DEAE-cellulose chromatography 
were pooled, dialyzed against 20 mM potassium phosphate 
buffer pH 7.0 and subjected to procainamide-Sepharose 
affinity chromatography as in [6]. The active fractions eluted 
with a 0.1 -0.6 M gradient of NaCl in the same buffer were 
pooled, dialyzed against the buffer and rechromatographed 
on procainamide-Sepharose. The column after washing with 
the buffer was eluted with 50 mM procainamide in the buffer 
and the active fractions dialyzed exhaustively against the buf- 
fer. The purified enzyme was homogenous by polyacrylamide 
gel electrophoresis [6]. 
The assay conditions for serum PsChE and AAA were the 
same as described before [6] except that the pH of the assay 
was 7.0. Protein was estimated according to Lowry et al. [14]. 
Chemical modijiications 
Modification of the enzyme was done by incubating 4- 
5 pg of the purified enzyme with different concentrations of 
the modifying agents (total volume 0.5 ml) at a given pH for 
a specified time at the indicated temperature (Table 1). At the 
end of incubation, the reaction mixture was diluted twofold 
with 20 mM potassium phosphate buffer pH 7.0 (in the case 
of diethylpyrocarbonate treatment 1 mM imidazole and in 
the case of (N02)3PhS03 treatment 0.5 mM sodium sulfite 
were included in the diluting buffer to terminate the modifica- 
tion), chilled in an ice bath and dialyzed at 4°C against 1 1 of 
20 mM potassium phosphate buffer, pH 7.0 for 16 - 20 h with 
three changes. (In separate experiments it was verified that 
at 0 - 4°C no detectable modification by N-acetylimidazole, 
tetranitromethane, phenylglyoxal and 2,4-pentanedione took 
place. But, a 108 - 116% activity was observed with acetic 
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anhvdride at the hizher concentrations of 7-15 mM.) RESULTS " 
Following this, the enzyme activities were determined. Every Modifications were carried out by the following reagents, experiment had a control that was subjected to the same HNBB and N-bromosuccinimide for modification of 
phenylglyoxal and 2,4-pentanedione for arginine; N-acetyl- ments where time-dependent modification was studied it was ensured that the control (unmodified) enzyme activities did imidazole and tetranitromethane for tyrosine; (N02)3PhS03 
and acetic anhydride for lysine. not change significantly with the time of incubation. 
h-t%mXnt without the modifying reagents. In  those experi- tryptophan residues; diethy~pryrocarbonate for histidine; 
Protect ion studies 
Protection experiments were performed by preincubating 
the purified enzyme at ambient temperature for 3 min with 
50 mM of butyrylcholine iodide (BCI) (substrate of PsChE) 
followed by the addition of the protein-modifying reagent in 
a total volume of 0.5 ml. (BCI formed a yellow colour or 
brown precipitate with high concentrations of tetranitro- 
methane as modifier and hence propionylcholine chloride was 
used under these conditions.) Protection studies were also 
carried out with the selective reversible inhibitors of PsChE 
namely ethopropazine (75 pM) and imipramine (100 pM) in 
a similar way. Dialysis was done as described above. 
Modification by HNBB and N-bromosuccinimide 
N-Bromosuccinimide and the more specific HNBB were 
used as reagents for modification oftryptophan residues. Both 
these reagents caused the inactivation of PsChE and AAA 
activities (Table 2). There was about 60% loss in both 
activities at 10 mM HNBB and about 85% loss at 25 pM N- 
bromosuccinimide. There was a parallel loss in both PsChE 
and AAA activities at the different concentrations of HNBB 
and N-bromosuccinimide used (Table 2). The presence of 
50 mM BCI as protector prevented the loss in both PsChE 
and AAA activities to a significant extent (Table 2). 
Modification hv diethylpyrocarbonate 
Spectral studies This reagent has been used for the modification of histidine 
Carbethoxylation of histidine by diethylpyrocarbonate 
[15] and 0-acetylation by acetic anhydride or N-acetyl- 
imidazole of tyrosine residues [16] were determined by ultra- 
violet absorption at 242 nm (for histidine) and 278 nm (for 
tyrosine). The extent of trinitrophenylation following the 
treatment with (N02)3PhS03 was determined by the method 
of Goldfarb [17] with slight modification. The modified 
enzyme mixture, after incubation was diluted to 1.0 ml with 
20 mM phosphate buffer, pH 8.0 containing 0.5 mM sodium 
sulfite to develop the colour and the incubation was continued 
for a further period of 5 min at 37°C and the resultant mixture 
was measured at different wavelengths within 400 - 450 nm. 
The trinitrophenylated complex showed a characteristic peak 
at 420 nm. All spectrophotometric measurements were made 
in an LKB Ultrospec spectrophotometer. 
Hydroxylumine treatment 
Acetylated or carbethoxylated enzymes were incubated 
with hydroxylamine (NH,OH) upto 1 M at pH 7.0-8.0 (pH 
adjusted with ammonia) in 0.5 ml at 3 7 T  for 1 h. The loss 
of enzyme activity was < 10% when the native enzyme was 
incubated with 1 M NH20H. Dialysis for removal of excess 
NH20H was done against 20 mM phosphate buffer, pH 7.0. 
SDS polyacrylamide gel electrophoresis 
Dialysed and concentrated samples of modified or un- 
modified enzymes with 1 % SDS were prepared by boiling at 
100°C for 3 min without 2-mercaptoethanol. In one case, the 
unmodified enzyme was prepared in a similar way with added 
5% 2-mercaptoethanol. All the samples were subjected to 
SDS gel electrophoresis in 10% gel according to Laemmli [18]. 
Standard marker proteins used to determine the molecular 
masses were immunoglobulin G (IgG) unreduced ( M ,  
150000), bovine serum albumin (Mr 68 000), IgG heavy chain 
( M ,  50000), ovalbumiun (M, 45000) and IgG light chain ( M ,  
23 500). 
[I 5 ,  231. With increasing concentrations of diethylpyro- 
carbonate there was a loss in activity of both PsChE and AAA 
which was about 60- 70% at 1OmM of the modifier (Table 2) .  
In the presence of BCI there was almost a 100% protection 
of both the activities against inactivation at the different con- 
centrations of the modifier used (Table 2). 
Diethylpyrocarbonate modification of histidine has been 
shown to be reversible by NH20H [15, 231. When the enzyme 
inactivated using 10 mM diethylpyrocarbonate was treated 
with 0.5 M NHzOH at pH 7.5 as given under Methods the 
activity was restored to 80% of the original. The enzyme 
inactivated at lower concentrations of the modifier were fully 
restored to the original activity upon N H 2 0 H  treatment. The 
possible involvement of lysine, tyrosine and serine in the 
modification by diethylpyrocarbonate [24] was excluded on 
the following bases. (a) Lysine and tyrosine modification by 
diethylpyrocarbonate is shown to be irreversible by N H 2 0 H  
[23]. (b) Spontaneous decarbethoxylation accompanied by 
reactivation in 29 min has been shown in the case of serine 
hydroxyl group modification by diethylpyrocarbonate [24] ; 
in the present experiment there was no reactivation of the 
inactivated enzyme even after dialysis for 16-20 h at pH 7.0. 
(c) The ultraviolet absorption at 242 nm characteristic of N- 
carbethoxyhistidine was increased as the amino acid was 
modified and there was no significant change at 278 nm ex- 
cluding the involvement of tyrosine residues [15, 251 (and data 
not shown). 
Modijication by (N0213PhS03  
Exposure of the enzyme to different concentrations of 
(N02)3PhS03 which reacts with amino groups resulted in the 
inactivation of both PsChE and AAA activities (Table 2) .  At 
20 mM (N02)3PhS03 60-70% of both activities were lost. 
There was a complete protection from loss of activities when 
the modification was carried out in the presence of BCI 
(Table 2). 
Fig. 1 shows the time-dependent inactivation by 10 mM 
(N02)3PhS03 of PsChE and AAA activities and the spectral 
changes associated with it. There was a progressive decrease 
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Fig. 1 .  Time-dependent inactivation of PsChE (0) and AAA (I} by 
niodification with 10 mM ( N 0 2 ) 3 P h S 0 3 .  Modification of the enzyme 
was carried out for the indicated time interval. Details of the modifica- 
tion procedure and assay are given under Methods. There was no 
change in control enzyme activity (100%) up to 40 min of incubation 
at  37°C. The inset in the figure shows the changes in the absorbance 
of the modified enzyme in the region of 400-450 nm, determined as 
described under Methods for the time intervals of (1) 0, (2) 10 min, 
(3) 20 min, (4) 30 min and ( 5 )  40 min of treatment with (N02)3PhS03 
in the activities with time. The time-dependent trinitro- 
phenylation of -NH2 groups in the modified enzyme, 
monitored in the range of 400-450 nm showed a peak at 
420 nm which increased with the time of treatment (inset of 
Fig. 1). 
Treatment of the (N02)3PhS03-modified enzyme with 
NH20H upto 1 M at pH 8.0 did not restore the lost activity 
to any significant extent suggesting that tyrosine groups were 
not involved in the inactivation by (N02)3PhS03. Moreover 
spectral studies of the (N02),PhS03-modified enzyme did not 
show any change in absorbance at 278 nm (characteristic of 
tyrosine). The involvement of cysteine -SH groups in the 
modification by (N02)3PhS03 resulting in inactivation was 
ruled out by the observation that N-ethylmaleimide upto 
20 mM and p-hydroxymercuribenzoate upto 2 mM (both 
- SH group modifying agents) did not have any effect on the 
enzyme activities. Assuming the non-involvement of an N- 
terminal amino acid, these results indicated that (NO2),- 
PhS03 modified the lysine-NH, groups in the enzyme re- 
sulting in the inactivation of PsChE and AAA. 
Results using acetic anhydride, another -NH2 group 
modifying agent will be described below. 
Modification by phenylglyoxal and 2,4-pentanedione 
These two specific modifiers interact with the guanido 
group of arginine residues. The results obtained on treatment 
of serum PsChE with these two reagents at different concen- 
trations are shown in Fig. 2. Unlike the parallel inactivation 
of both PsChE and AAA, resulting from the modifications 
described so far, modification by phenylglyoxal and 2,4- 
pentanedione caused a progressive activation of PsChE alone 
without affecting AAA to any significant extent. At 20 mM 
of phenylglyoxal, PsChE activity was 195% of the control and 
at 10 mM of 2,4-pentanedione it was 180%. BCI as protector 
could completely reverse this activation (Fig. 2). The time- 
dependent modification by phenylglyoxal and 2,4- 
pentanedione further corroborated their effect in the activa- 
tion of PsChE without affecting AAA (Fig. 3). With 5 mM of 
each of these modifiers, PsChE activity rose up to 160- 170% 
at 40 min. BCI could completely protect PsChE activity from 
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activation by both the modifiers (Fig. 3). Taken together, these 
results suggested that arginine modification altered only the 
PsChE activity (without affecting AAA) and that this altera- 
tion could be prevented by BCI. 
Modification by N-acetylimiduzole and tetranitromethane 
Both N-acetylimidazole and tetranitromethane have been 
used as modifying agents selectively for tyrosine [26 - 281. The 
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Fig. 2. Effect of modification with increasing concentrations of' 
phenylglyosal ( A )  and2,l-pentanedione ( B )  on PsChE (0) and A A A 
(0 ) activity. The modification was carried out in the absence (-) 
or presence (----) of BCI as protector. Details of the modification 
procedure and assay are given under Methods. The control enzyme 
activity at  zero concentration of the modifier is taken as 100% 
changes in the activity of PsChE and AAA resulting from 
modification by these agents at different concentrations are 
shown in Fig. 4. Both enzyme activities showed a similar 
pattern of changes. At 10 mM and 25 mM N-acetylimidazole 
there was an increase in activity (about 135% of original 
activity at 25 mM). At 50 - 100 mM the activity was about 
100-90Y0 of the original and above 100 mM there was a fall 
in activity (Fig. 4A). The inset in Fig. 4A shows the change 
in absorbance at 278 nm resulting from modification by 
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Fig. 4. Changes in the activity of PsChE ( 0 )  and A A A  (0) by 
modfication qf the enzyme with N-acetylimidazole ( A )  and 
tetranitromethane ( B )  at different concentrations. The enzyme was 
incubated at  37°C with the modifying agent at the respective 
concentration for 20 min (with N-acetylimidazole) or 30 min (with 
tetranitromethane). The curve in the inset of A shows the changes in 
absorbance at 278 nm of the modified enzyme samples. Details of 
the modification procedure and assay of enzymes are given under 
Methods. The control enzyme activity at  zero concentration of 
modifier is taken as 100% 
A r 
Fig. 3. Changes in activities of PsChE ( 0 )  and A A A  (0) as afunction of time of modification with 5 mMphenylglyoxal ( A )  or 5 mM 2,4- 
pentanedione ( B )  in the absence (-) or presence (----) of BCI as protector. Details of the modification and assay are given under 
Methods. There was no detectable change in control enzyme activity (100%) up to 40 min of incubation at  37°C 
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Fig. 5 .  The activation of PsChE ( 0 )  and A A A  ( 0 )  as a,function of 
time by mod$cation with 25 mM N-acetylimidazole ( A )  or 0.021 mM 
tetrunitromethane ( B )  in the absence (-) or presence (----) qf 
BCI as protectar. The enzyme was incubated for the desired period at 
37°C for modification. Details of the modification procedure and 
assay are given under Methods. There was no change in control 
enzyme activity (100%) up to 30 min of incubation at 37°C 
N-acetylimidazole at the different Concentrations. Similar 
activity changes were observed when tetranitromethane was 
used for modification. At 0.021 mM there was an activation 
up to 150%, between 0.042 and 0.42 mM, the changes were 
minimal and above 0.42 mM there was a progressive fall in 
activity (Fig. 4 B). These patterns of concentration-dependent 
changes in activity were confirmed in several batches of the 
purified serum PsChE. The results suggested that at lower 
concentrations of N-acetylimidazole or tetranitromethane the 
amino acids modified caused an increase in activity whereas 
at higher concentrations, the modified amino acids caused a 
decrease. 
The two phases of the activity changes became more 
apparent when modification was carried out with a low or 
high concentration of these two modifiers for different periods 
(Figs. 5 and 6). Fig. 5 shows the changes in activity when 
modification was carried out with 25 mM N-acetylimidazole 
for different periods upto 30 min in the absence or presence 
of BCI as a protector. There was a continuous increase in 
activity of both PsChE and AAA upto about 165% of original 
at 30 min in the absence of BCI. In the presence of BCI as 
protector during modification, there was a small reduction in 
the enhancement of activity but the enhancement could not 
be abolished by the protector. Similar results were shown 
when modification by 0.21 mM tetranitromethane for dif- 
ferent periods up to 30 min in the absence or presence of BCI 
was carried out (Fig. 5 B). 
Fig. 6A shows the changes in activity when modification 
was carried out with a high concentration (200 mM) of N- 
acetylimidazole for different periods in the absence and pres- 
ence of BCI as protector. There was a continuous fall in both 
PsChE and AAA activities up to 15% of original at 30 min 
in the absence of the protector. Modification in the presence 
of the protector however resulted in not only a complete 
reversal of the fall in activity but also an enhancement in 
activity upto 165% at 30 min similar to observations made 
when modification was carried out with a low concentration 
(25 mM) of N-acetylimidazole as shown in Fig. 5A. Fig. 6B 
shows the activity changes when a high concentration 
(4.2 mM) of tetranitromethane was used for modification for 
different periods, either in the presence or absence of the 
protector; the results were similar to those shown in Fig. 6A. 
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Fig. 6. Changes in the activity of PsChE ( 0 )  and A A A  ( 0 )  as a 
function of time by modijicution with 200 m M  N-acetylimiduzole ( A )  
or 4.2 m M  tetranitromethane ( B )  in the absence (-) or presence 
(----) ojBCI [ A )  arzdpropionylcholine chloride ( B )  asprotector. The 
enzyme was incubated for the desired period at 37’C for modification. 
Details of the modification procedure and assay are given under 
Methods. There was no change in control enzyme activity (100%) up 
to 30 min of incubation at 37°C 
The nearly identical pattern of changes in enzyme activities 
by N-acetylimidazole and tetranitromethane suggested that 
both the agents modified tyrosine residues. Spectral studies 
indicated a progressive fall in absorption at 278 nm 
(characteristic for tyrosine) after modification of the enzyme 
with N-acetylimidazole at different concentrations (1 0 - 
300 mM, inset of Fig. 4A). It has been shown that tyrosine 
modified by N-acetylimidazole is deacetylated in the presence 
of NHzOH at alkaline pH [29]. We found that the activation 
of PsChE and AAA after modification by 25 mM N- 
acetylimidazole was completely reversible on incubation 
either with 0.8 M NH20H at pH 7.0 or with 0.2 M NH20H 
at pH 8.0. On the other hand, the inactivated PsChE and AAA 
obtained by the modification of the enzyme with 200 mM N- 
acetylimidazole could be reversed only to about 40 - 50% by 
incubation with 1 M NH20H at pH 8.0. Whether this partial 
reversibility by NH20H is characteristic of the ‘buried’ nature 
of the tyrosine residues involved [29] or whether any amino 
acids other than tyrosine (such as lysine; see below for acetyla- 
tion by acetic anhydride) are also modified at the higher 
concentration of N-acetylimidazole cannot be conclusively 
stated. However, the possibility of the activity changes due 
to histidine modification by N-acetylimidazole was excluded 
because acetylation of this amino acid is spontaneously re- 
versed [26, 281. The involvement of -SH groups in the 
modification by tetranitromethane [27] resulting in activity 
changes was also excluded because N-ethylmaleimide upto 
20 mM and p-hydroxymercuribenzoate upto 2 mM did not 
influence PsChE or AAA activities [30]. 
The results shown in Fig. 5 indicated that the tyrosine 
residues modified by the low concentrations of N-acetyl- 
imidazole (25 mM) or tetranitromethane (0.021 mM) had the 
following features. (a) Their modification resulted in an 
activation of the PsChE and AAA activities. (b) They 
appeared to be a class of tyrosine residues which were more 
amenable to modification as compared to the residues whose 
modification needed a higher concentration of the modifiers 
and resulted in the inactivation of the enzyme. (c) They did 
not appear to be at the active site of the enzyme because of 
the relatively poor protection offered by the substrate BCI 
against modification; on the other hand, the amino acids 
responsible for the inactivation phase of the enzyme at higher 
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Fig. 7. Eflect of increusing concentrations of ucetic unhydride modifier 
on PsChE ( 0 )  and A A A  (0) uctivites in the absence (-) or 
presence (----) of’ BCI. (0-0 PsChE and (W-W) AAA 
activities of the modified enzyme after treatment with 0.2 M N H 2 0 H  
at pH 7.5. The inset shows the absorbance of the modified enzyme 
( 0 )  at 278 nm (for tyrosine) and (0) 420 nm (for free -NHz groups) 
after modification by acetic anhydridc at  different concentrations. 
The details of modification, assay and NHZOH treatment are given 
under Methods. The control enzyme activity at  zero concentration of 
the modifier is taken as 100% 
concentrations of N-acetylimidazole and tetranitromethane 
could be completely protected by BCI or propionylcholine 
chloride. (d) The activation of PsChE and AAA observed 
while protecting modification at higher concentrations of N- 
acetylimidazole and tetranitromethane (Fig. 6) could be due 
to the availability of the modifying agents exclusively for the 
more amenable class of tyrosine residues which were only 
poorly protected by BCI. This also corroborated the view that 
the more amenable class of tyrosine residues responsible for 
activation of PsChE and AAA were not at  the active site. 
Modification by ace ric anhydride 
Acetic anhydride is known to acetylate the lysine -NH2 
groups and tyrosine hydroxyl groups in proteins [9, 16, 261. 
Fig. 7 shows the effect of modification on the enzyme when 
different concentrations of acetic anhydride were used. There 
was an activation of both PsChE and AAA to about 140% 
of original activity at 5 mM acetic anhydride followed by 
a decline in activity and progressive inactivation at higher 
concentrations of acetic anhydride (Fig. 7). The results 
suggested that at lower concentrations of acetic anhydride 
there was an activation of both PsChE and AAA and at higher 
concentrations an inactivation, a phenomenon similar to that 
observed when N-acetylimidazole and tetranitromethane were 
used for modification of tyrosine residues (see Fig. 4). In order 
to differentiate tyrosine residues and - NH2 residues involved 
in acetylation, the modified enzyme obtained at each of the 
different concentrations of acetic anhydride was treated with 
NH20H (0.2 M at pH 7.5 or 1 M NHzOH at pH 8.0). The 
results shown in Fig. 7 indicates that the activation of the 
enzyme at lower concentrations of acetic anhydride was re- 
versed by N H 2 0 H  but the inactivation was unaffected 
suggesting that acetylation of tyrosine residues was respon- 
sible for the activation whereas acetylation of - NH2 groups 
(and possibly ‘buried’ tyrosine residues) was responsible for 
the inactivation. The available free -NH2 groups after acetic 
anhydride modification was estimated by trinitrophenylation 
with (N02)3PhS03 and measuring the absorbance at 420 nm 
(inset of Fig. 7). As shown in the inset, up to 5 mM acetic 
anhydride the decrease in 420-nm absorbance was insignifi- 
cant but above 5 mM there was a progressive decline in 
absorbance. Moreover the changes in absorbance at 278 nm 
of the modified enzyme shown in the inset supported the 
acetylation of tyrosine residues. When BCI was used as a 
protector during modification, the activation of the enzyme 
alone was seen at all concentrations of acetic anhydride in- 
cluding the higher concentrations (Fig. 7). This observation 
was similar to the effect of BCI as protector during modifica- 
tion of tyrosine residues by N-acetylimidazole (see Figs. 5 
and 6). Taken together these results indicated that tyrosine 
residues present at a site different from the active site, and 
more amenable for acetylation, were responsible for the 
activation. With BCI as protector, all the available acetic 
anhydride was used exclusively for modification of these 
tyrosine residues because of the selective protection by BCI 
of the active-site lysine (and possibly tyrosine) residues. 
Use of’ethopropazine and imipran7ine as protecting agents 
Ethopropazine is a selective reversible inhibitor of PsChE 
[19, 21, 221. Yet another reversible inhibitor is imipramine 
[20, 221. Although conclusive evidence is lacking, it is 
suggested that ethopropazine may be acting as a non-competi- 
tive inhibitor [21, 221 and imipramine as an allosteric competi- 
tive inhibitor [20, 221. We used both these inhibitors as pro- 
tectors during the various chemical modification experiments 
at different concentrations of the modifier. Neither of these 
inhibitors (75 pM ethopropazine and 100 pM imipramine) 
showed any protective effect against inactivation of PsChE 
and AAA when modifications were carried out with HNBB, 
N-bromosuccinimide and (N02)3PhS0,. This was in contrast 
to the protection offered by BCI in the above modification 
procedures. On the other hand, the activation of PsChE re- 
sulting from modification of arginine residues by 
phenylglyoxal and 2,4-pentanedione could be protected by 
both ethopropazine and imipramine (data not shown), similar 
to observations made with BCI as protector. With diethyl- 
pyrocarbonate as modifier, ethopropazine could protect both 
PsChE and AAA from inactivation while imipramine was 
ineffective as a protector (data not shown). These results 
suggested different binding sites for BCI, ethopropazine and 
imipramine but that a modifiable arginine residue or residues 
may be common amongst them. 
The results obtained on the use of ethopropazine and 
imipramine as protectors during modification by N-acetyl- 
imidazole are shown in Fig. 8. It has already been pointed 
out (Fig. 5 )  that at low concentration of N-acetylimidazole 
(25 mM) there was an activation of PsChE and AAA and that 
this may be due to modification of a class of tyrosine residues 
not protectable by BCI and therefore not present at the active 
site. With ethopropazine and imipramine as protectors the 
activation was abolished and instead inactivation of PsChE 
and AAA was observed (Fig. 8A). These results indicate that 
the non-active-site tyrosine residues were protected from 
modification by ethopropazine and imipramine and therefore 
all the N-acetylimidazole was exclusively utilized for the 
modification of the active-site tyrosine (and possibly lysine) 
residues resulting in the inactivation of the enzyme. These 
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Fig. 8. Chunges in activity of PsChE ( 0 )  and A A A  ( 0 )  as a function 
of time by modgication with ( A )  25 mM or (3) 200 mM N-acetyl- 
imidusole in the absence (-) and the presence I----) of etho- 
propazine or imipramine as protectors during modification. Details of 
the protection procedure and assay are given under Methods. There 
was no change in control enzyme activity (100%) up to 30 min of 
incubation 
conclusions were further confirmed when it was found that 
ethopropazine and imipramine could not protect against the 
inactivation of PsChE and AAA at high concentration 
(200 mM) of N-acetylimidazole (Fig. 8 B). These results in- 
dicated that ethopropazine and imipramine were capable of 
selectively protecting the non-active-site tyrosine residues 
from acetylation by N-acetylimidazole. 
A further line of evidence to suggest that ethopropazine 
and imipramine bind to the non-active-site tyrosine residues 
rather than the active-site tyrosine residues came from 
modification studies using acetic anhydride. Fig. 9 shows 
modification by acetic anhydride at different concentrations 
in the absence and pressure of ethopropazine and imipramine. 
In the presence of either ethopropazine or imipramine a pro- 
gressive fall in both PsChE and AAA activities was observed, 
suggesting the selective protection of the non-active-site 
tyrosine residues by the inhibitors from acetylation and the 
consequent availability of the modifier exclusively for the 
acetylation of the active-site tyrosine (and possibly lysine) 
residues. 
Rates of PsChE activity changes by the various modifiers 
The rates of activity changes were studied at three or four 
time intervals at three different concentrations of each of the 
following modifying agents : N-bromosuccinimide, diethylpy- 
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Fig. 9. e f e c t  of increasing amounts of acetic anhydride as modifier on 
PsChE (0  ) and A A A  (0 ) activities in the absence (-) orpresence 
(----) of ethopropazine or imipramine as protectors during modifica- 
tion. Details of the protection procedure and assay are given under 
Methods. The control enzyme activity at zero concentration of the 
modifier is taken as 100% 
rocarbonate, N-acetylimidazole, (NO2),PhSO3 and phenyl- 
glyoxal. Semilogarithmic plots of residual activity against 
time were linear indicating pseudo-first-order rate kinetics 
up to 70 - 80% inactivation by N-bromosuccinimide, 
diethylpyrocarbonate, (N02),PhS03 and high concentrations 
(above 200 mM) of N-acetylimidazole (data not shown). A 
slower rate of inactivation was observed beyond 70% in- 
activation in the case of N-bromosuccinimide and beyond 
80% inactivation in the case of diethylpyrocarbonate. The 
rate of activation by phenylglyoxal and by low concentrations 
of N-acetylimidazole (below 20 mM) also followed a pseudo- 
first-order process up to about 170% activity in the case of 
phenylglyoxal and 140% activity in the case of N-ace- 
tylimidazole. A slower rate of increase beyond this limit was 
observed for each of these two modifiers. 
SDS-gel electrophoresis of the tnodified and unmodifed PsChE 
SDS-gel electrophoresis of the unmodified enzyme after 
reduction by 2-mercaptoethanol showed the predominance of 
the monomeric form of PsChE (Mr  92000) (Fig. 10). Under 
non-reducing conditions, SDS gel electrophoresis gave both 
the monomer and the dimer (Mr 183000) [ 5 ,  311. Samples of 
enzyme modified by the various reagents were subjected to 
SDS-gel electrophoresis under non-reducing conditions. All 
of them gave the dimer and monomer like the unmodified 
enzyme and there was no evidence of a complete conversion 
to the monomer subunit in any of the modified enzymes 
(Fig. 10). 
DISCUSSION 
The present studies were undertaken to delineate the 
active-site amino acid residues involved in the PsChE and 
AAA activities of the bifunctional PsChE enzyme from 
human serum. Either one specific reagent or more than one 
have been used for the modification of each amino acid in the 
purified enzyme. In all cases either spectral studies or other 
supporting evidence has been presented to exclude the 
possibility of the involvement of alternative amino acids 
during modification. BCI, the substrate of PsChE, has been 
used as a protective agent during modifications in order to 
identify whether the modified amino acid belongs to the active 
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Fig. 10. SDS slab gel electrophoresis of the modified and unmodified 
enzyme preparation (8 pg) in the presence of 1% SDS). Lane 1 - 5 
are the unreduced modified enzyme samples, modified by (1) 10 mM 
HNBB for 30 min, (2) 10 mM diethylpyrocarbonate for 15 min, (3) 
20 mM (N02),PhS03 for 30 min, (4) 20 mM phenylglyoxal for 
30 min and (5) 200 mM N-acetylimidazole for 20 min. Details of 
modification are given under Methods. Lane (6) is unmodified enzyme 
without 2-mercaptoethanol and lane (7) unmodified enzymc with 2- 
mercaptoethanol. Arrows b and -b respectively indicate the 
dimeric and monomeric form of the enzyme 
site or not. It is to be noted that modification of amino acids 
in an enzyme may alter not only the binding and hydrolysis 
of the substrate but also result in conformational changes that 
in turn can influence the catalytic activity. Moreover the actual 
participation of the amino acids in catalysis may involve a 
more complex mechanism than that which is suggested by the 
amino acid modification studies alone [36]. Nevertheless, a 
chemical modification study of the kind described here in- 
volving several modifying agents for the different amino acids 
and results complementing each other provides valuable infor- 
mation on the amino acid residues involved in catalytic 
activity. 
Of the four amino acids, viz tryptophan, histidine, lysine 
and arginine, modification of the first three resulted in the 
inactivation of both PsChE and AAA, suggesting that these 
amino acids may be present at the active site of both enzymes. 
BCI, the substrate for PsChE, could prevent both PsChE and 
AAA inactivation resulting from modification of these three 
amino acids, suggesting that tryptophan, lysine and histidine 
may be present at a common active site of PsChE and AAA. 
Arginine modification, however, resulted in the activation of 
PsChE (that could be prevented by BCI) without affecting 
AAA. This suggested that the modifiable arginine residue 
present at the active site of PsChE was not involved in the 
active site of AAA. Altough unusual, arginine modification 
resulting in the activation of an enzyme is known [37]. The 
collective results thus suggest non-identical but overlapping 
active sites for PsChE and AAA. 
Tyrosine modification by three different reagents, namely 
N-acetylimidazole, tetranitromethane and acetic anhydride, 
provides evidence for the existence of one or more tyrosine 
residues that are readily susceptible to modification resulting 
in the activation of both PsChE and AAA and that do not 
seem to belong to the active site of PsChE and AAA. Experi- 
ments leading to such a conclusion are described in detail in 
Results. More interestingly, ethopropazine and imipramine, 
two reversible inhibitors of PsChE, could protect the non- 
active-site tyrosine residues against modification by N-acetyl- 
imidazole and acetic anhydride, indicating that the binding 
site of these inhibitors involves the non-active-site tyrosine 
residues. 
Modification of tyrosine residues has been reported to 
result in the activation of the esterase activity of a number 
of proteases like chymotrypsin, trypsin, carboxypeptidase A, 
pepsin, elastase and thrombin [8 - 121. This enhancement in 
activity has been attributed to the active-site tyrosine residues 
in carboxypeptidase A and secondary-site tyrosine residues in 
pepsin [12, 381. It remains to be seen whether modification of 
the non-active-site tyrosine residues in human serum PsChE 
that results in an increase in the PsChE and AAA activity 
would also result in an enhancement of its reported protease 
activity. 
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